Yndart Arias Adriana, Vadell Kamila, Vashist Arti, Kolishetti Nagesh, Lakshmana Madepalli K, Nair Madhavan, Liuzzi Juan P
Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, United States.
Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.
Front Pharmacol. 2024 Sep 11;15:1403147. doi: 10.3389/fphar.2024.1403147. eCollection 2024.
Finding new strategies to treat cognitive disorders is a challenging task. Medication must defeat the blood-brain barrier. Cannabidiol (CBD), a non-intoxicating compound of the cannabis plant, has gained recognition as a nutraceutical for its potential effectiveness in treating anxiety, oxidative stress, convulsions, and inflammation. However, the dose, tolerable upper intake, formulation, administration routes, comorbidities, diet, and demographic factors to reverse cognitive impairments have not been completely explored. Trials using CBD as a primary intervention have been conducted to alleviate cognitive issues. This review evaluates the benefits of CBD supplementation, research design, formulations, and outcomes reported in randomized clinical trials.
An evidence-based systematic literature review was conducted using PUBMED and the Florida International University Research Library resources. Fourteen randomized trials were selected for review, and their designs and outcomes were compared conceptually and in the form of resume tables.
CBD showed improvement in anxiety and cognitive impairments in 9 out of 16 analyzed trials. However, the variability could be justified due to the diversity of the trial designs, underpowered studies, assayed population, uncontrolled results for comorbidities, medications, severity of drug dependence, compliances, and adherences. Overall, oral single doses of 200 mg-1,500 mg or vaporized 13.75 mg of CBD were shown to be effective at treating anxiety and cognition with a good safety profile and no drug addiction behaviors. Conversely, results that did not have a significant effect on treating cognitive impairments can be explained by various factors such as THC or other abuse drugs masking effect, low dose, and unknown purity of CBD. Furthermore, CBD shows potential properties that can be tested in the future for Alzheimer's disease.
As medical cannabis becomes more accessible, it is essential to understand whether medication rich in CBD exerts a beneficial effect on cognitive disorders. Our study concludes that CBD is a promising candidate for treating neurocognitive disorders; however, more studies are required to define CBD as a therapeutic candidate for managing cognitive disorders.
寻找治疗认知障碍的新策略是一项具有挑战性的任务。药物必须突破血脑屏障。大麻二酚（CBD）是大麻植物中的一种无毒性化合物，因其在治疗焦虑、氧化应激、惊厥和炎症方面的潜在功效而被视为一种营养保健品。然而，逆转认知障碍的剂量、可耐受的最高摄入量、制剂、给药途径、合并症、饮食和人口统计学因素尚未得到充分研究。已经开展了以CBD作为主要干预措施的试验来缓解认知问题。本综述评估了随机临床试验中报道的CBD补充剂的益处、研究设计、制剂和结果。
利用PUBMED和佛罗里达国际大学研究图书馆资源进行了一项基于证据的系统文献综述。选择了14项随机试验进行综述，并从概念上以及以摘要表的形式比较了它们的设计和结果。
在16项分析试验中的9项中，CBD显示出焦虑和认知障碍有所改善。然而，由于试验设计的多样性、研究力度不足、受试人群、合并症、药物、药物依赖严重程度、依从性和坚持性的结果未得到控制，这种变异性是可以解释的。总体而言，口服单剂量200毫克至1500毫克或雾化13.75毫克的CBD在治疗焦虑和认知方面显示出有效性，具有良好的安全性，且无药物成瘾行为。相反，对治疗认知障碍没有显著效果的结果可以由各种因素来解释，如四氢大麻酚（THC）或其他滥用药物的掩盖效应、低剂量以及CBD的纯度未知。此外，CBD显示出未来可用于阿尔茨海默病测试的潜在特性。
随着医用大麻的获取变得更加容易，了解富含CBD的药物是否对认知障碍产生有益影响至关重要。我们的研究得出结论，CBD是治疗神经认知障碍的一个有前景的候选药物；然而，需要更多的研究来将CBD定义为管理认知障碍的治疗候选药物。
